Managing Director, Bay City Capital
Ashley Dombkowski, Ph.D. is a Managing Director with Bay City Capital, a $1.6 billion venture capital firm focused on life sciences. She has nearly 20 years of experience as an investor, operating executive, and entrepreneur in the healthcare field. Prior to joining Bay City, she served as Chief Business Officer and Vice President of Operations for 23andMe, where she oversaw the company’s finance and operations activities and had responsibility for the company’s long term business strategy focused on database growth plans, R&D productivity, and profitability.
Prior to joining 23andMe, Ashley was a Managing Director with venture capital firm MPM Capital where she also served as a member of the firm’s Investment Committee. During her years at MPM she focused on developing innovative biotechnology, medical device, and healthcare IT companies, including companies such as 23andMe, Adolor, Alnara, BioVitrum, Epizyme, iPierian, Neosil, Nevro, Rigel, and Tercica. Prior to this, she was a Healthcare Equity Analyst for hedge fund Tiger Management L.L.C. and for institutional asset management firm Dresdner RCM Global Investors.
Ashley holds a Ph.D. in Mathematics from Rice University and received her B.A. in Mathematics from Wellesley College. She has been widely quoted in publications ranging from Nature to The Wall Street Journal and she has appeared in media outlets ranging from CNBC to TedMed. She was recognized as one of the 100 Most Influential Women in Business by the San Jose/Silicon Valley Business Journal in 2010. She is a member of the Board of Directors of USA Volleyball and serves as Chair of the Audit, Finance, and Budget committee.